Why the study?
Does combined anti-platelet therapy with ASA and ticlopidine prevent sustained platelet activation and slow-flow phenomenon after successful PTCA and lysis for a large intracoronary thrombus in AMI?
Does combined anti-platelet therapy with ASA and ticlopidine prevent sustained platelet activation and slow-flow phenomenon after successful PTCA and lysis for a large intracoronary thrombus in AMI?
Sustained platelet activation and progressive slow-flow phenomenon can occur despite combined anti-platelet therapy following successful treatment of a large intracoronary thrombus in AMI.
Persistent activation and slow-flow may occur despite ASA+ticlopidine post-AMI thrombus; hypothesis-generating case leaves optimal regimens open.
A patient with AMI caused by a large thrombus in the proximal LAD was successfully treated with PTCA and an intracoronary lysis combined with the platelet-receptor antagonist c7E3. Analysis of cellular hemostasis after 1 and 6 months revealed a sustained platelet activation despite combined anti-platelet therapy with ASA and ticlopidine. A progredient slow-flow phenomenon appeared during control angiographies, confirmed by intracoronary Doppler examination.
No takes yet. Share an insight, caveat, or question.
Haude et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: